Orchid Pharma gets EIR report from FDA
04 January 2016 | News | By BioSpectrum Bureau
Orchid Pharma gets EIR report from FDA
The facility was inspected by US health regulator in the month of May 2015
Orchid Pharma has informed BSE that it has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) based on the successful inspection closure for the formulation manufacturing facility located at Irungattukottai, Sriperumbudur, Kancheepuram District, India.
The facility was inspected by US health regulator in the month of May 2015.
Orchid Pharma is present in segments such as anti-infectives, anti-inflammatory, central nervous system, cardio vascular, nutraceuticals and oral as well as sterile products.
